ABCB-101 (AbbVie Partnered)
Oncology (Undisclosed)
Pre-clinicalActive Discovery
Key Facts
About AbCellera
AbCellera is a pioneer in AI-powered antibody discovery, operating a unique platform that integrates microfluidics, high-throughput screening, and machine learning to rapidly identify therapeutic antibodies from natural immune responses. The company's business model is primarily partnership-driven, collaborating with major pharmaceutical companies to advance drug candidates while also building its own pipeline. Key achievements include its critical role in the discovery of bamlanivimab for COVID-19 and its successful IPO in 2020. Its strategic direction focuses on expanding its internal pipeline, scaling its platform capabilities, and deepening its partnerships across multiple therapeutic areas.
View full company profileTherapeutic Areas
Other Oncology (Undisclosed) Drugs
| Drug | Company | Phase |
|---|---|---|
| NX-0479 (GS-6791) | Nurix Therapeutics | Preclinical |
| ABCB-103 (Gilead Partnered) | AbCellera | Pre-clinical |